Researchers have reported encouraging results from preclinical studies of SOL-257, an experimental gene therapy designed to address underlying disease mechanisms in ALS. In two mouse models of ALS, the therapy improved motor function and extended survival, suggesting it may help slow disease progression rather than just manage symptoms. These findings